Browse PLA2G2A

Summary
SymbolPLA2G2A
Namephospholipase A2, group IIA (platelets, synovial fluid)
Aliases PLA2B; MOM1; PLA2S; PLAS1; GIIC sPLA2; NPS-PLA2; group IIA phospholipase A2; non-pancreatic secretory phosph ......
Chromosomal Location1p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Peripheral membrane protein Secreted
Domain PF00068 Phospholipase A2
Function

Catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides (PubMed:2925633). Thought to participate in the regulation of phospholipid metabolism in biomembranes including eicosanoid biosynthesis. Independent of its catalytic activity, acts as a ligand for integrins (PubMed:18635536, PubMed:25398877). Binds to and activates integrins ITGAV:ITGB3, ITGA4:ITGB1 and ITGA5:ITGB1 (PubMed:18635536, PubMed:25398877). Binds to a site (site 2) which is distinct from the classical ligand-binding site (site 1) and induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:25398877). Induces cell proliferation in an integrin-dependent manner (PubMed:18635536).

> Gene Ontology
 
Biological Process GO:0006575 cellular modified amino acid metabolic process
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006654 phosphatidic acid biosynthetic process
GO:0006658 phosphatidylserine metabolic process
GO:0006820 anion transport
GO:0006869 lipid transport
GO:0010742 macrophage derived foam cell differentiation
GO:0010743 regulation of macrophage derived foam cell differentiation
GO:0010744 positive regulation of macrophage derived foam cell differentiation
GO:0010876 lipid localization
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015908 fatty acid transport
GO:0015909 long-chain fatty acid transport
GO:0016042 lipid catabolic process
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0032309 icosanoid secretion
GO:0034367 macromolecular complex remodeling
GO:0034368 protein-lipid complex remodeling
GO:0034369 plasma lipoprotein particle remodeling
GO:0034374 low-density lipoprotein particle remodeling
GO:0036148 phosphatidylglycerol acyl-chain remodeling
GO:0036149 phosphatidylinositol acyl-chain remodeling
GO:0036150 phosphatidylserine acyl-chain remodeling
GO:0036151 phosphatidylcholine acyl-chain remodeling
GO:0036152 phosphatidylethanolamine acyl-chain remodeling
GO:0042742 defense response to bacterium
GO:0043410 positive regulation of MAPK cascade
GO:0046470 phosphatidylcholine metabolic process
GO:0046471 phosphatidylglycerol metabolic process
GO:0046473 phosphatidic acid metabolic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046942 carboxylic acid transport
GO:0050482 arachidonic acid secretion
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050830 defense response to Gram-positive bacterium
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0071715 icosanoid transport
GO:0071825 protein-lipid complex subunit organization
GO:0071827 plasma lipoprotein particle organization
GO:0090077 foam cell differentiation
GO:0097006 regulation of plasma lipoprotein particle levels
GO:0097164 ammonium ion metabolic process
GO:0098542 defense response to other organism
GO:1903963 arachidonate transport
Molecular Function GO:0004620 phospholipase activity
GO:0004623 phospholipase A2 activity
GO:0005543 phospholipid binding
GO:0016298 lipase activity
GO:0047498 calcium-dependent phospholipase A2 activity
GO:0052689 carboxylic ester hydrolase activity
Cellular Component GO:0030141 secretory granule
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04270 Vascular smooth muscle contraction
hsa04972 Pancreatic secretion
hsa04975 Fat digestion and absorption
hsa00564 Glycerophospholipid metabolism
hsa00565 Ether lipid metabolism
hsa00590 Arachidonic acid metabolism
hsa00591 Linoleic acid metabolism
hsa00592 alpha-Linolenic acid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1482788: Acyl chain remodelling of PC
R-HSA-1482839: Acyl chain remodelling of PE
R-HSA-1482925: Acyl chain remodelling of PG
R-HSA-1482922: Acyl chain remodelling of PI
R-HSA-1482801: Acyl chain remodelling of PS
R-HSA-6803157: Antimicrobial peptides
R-HSA-1483206: Glycerophospholipid biosynthesis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1483257: Phospholipid metabolism
R-HSA-1483166: Synthesis of PA
Summary
SymbolPLA2G2A
Namephospholipase A2, group IIA (platelets, synovial fluid)
Aliases PLA2B; MOM1; PLA2S; PLAS1; GIIC sPLA2; NPS-PLA2; group IIA phospholipase A2; non-pancreatic secretory phosph ......
Chromosomal Location1p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PLA2G2A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPLA2G2A
Namephospholipase A2, group IIA (platelets, synovial fluid)
Aliases PLA2B; MOM1; PLA2S; PLAS1; GIIC sPLA2; NPS-PLA2; group IIA phospholipase A2; non-pancreatic secretory phosph ......
Chromosomal Location1p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PLA2G2A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPLA2G2A
Namephospholipase A2, group IIA (platelets, synovial fluid)
Aliases PLA2B; MOM1; PLA2S; PLAS1; GIIC sPLA2; NPS-PLA2; group IIA phospholipase A2; non-pancreatic secretory phosph ......
Chromosomal Location1p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PLA2G2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2940.782
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7310.734
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.1140.326
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1150.885
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4240.82
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2670.899
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.040.973
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0970.956
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2390.895
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.6420.466
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 284.2770.128
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.9520.0216
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PLA2G2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPLA2G2A
Namephospholipase A2, group IIA (platelets, synovial fluid)
Aliases PLA2B; MOM1; PLA2S; PLAS1; GIIC sPLA2; NPS-PLA2; group IIA phospholipase A2; non-pancreatic secretory phosph ......
Chromosomal Location1p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLA2G2A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPLA2G2A
Namephospholipase A2, group IIA (platelets, synovial fluid)
Aliases PLA2B; MOM1; PLA2S; PLAS1; GIIC sPLA2; NPS-PLA2; group IIA phospholipase A2; non-pancreatic secretory phosph ......
Chromosomal Location1p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLA2G2A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLA2G2A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPLA2G2A
Namephospholipase A2, group IIA (platelets, synovial fluid)
Aliases PLA2B; MOM1; PLA2S; PLAS1; GIIC sPLA2; NPS-PLA2; group IIA phospholipase A2; non-pancreatic secretory phosph ......
Chromosomal Location1p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLA2G2A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPLA2G2A
Namephospholipase A2, group IIA (platelets, synovial fluid)
Aliases PLA2B; MOM1; PLA2S; PLAS1; GIIC sPLA2; NPS-PLA2; group IIA phospholipase A2; non-pancreatic secretory phosph ......
Chromosomal Location1p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PLA2G2A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPLA2G2A
Namephospholipase A2, group IIA (platelets, synovial fluid)
Aliases PLA2B; MOM1; PLA2S; PLAS1; GIIC sPLA2; NPS-PLA2; group IIA phospholipase A2; non-pancreatic secretory phosph ......
Chromosomal Location1p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PLA2G2A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPLA2G2A
Namephospholipase A2, group IIA (platelets, synovial fluid)
Aliases PLA2B; MOM1; PLA2S; PLAS1; GIIC sPLA2; NPS-PLA2; group IIA phospholipase A2; non-pancreatic secretory phosph ......
Chromosomal Location1p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PLA2G2A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PLA2G2A.
ID Name Drug Type Targets #Targets
DB00328IndomethacinSmall MoleculeAKR1C3, GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS29
DB00586DiclofenacSmall MoleculeALOX5, ASIC1, KCNQ2, KCNQ3, PLA2G2A, PTGS1, PTGS2, SCN4A8
DB01381Ginkgo bilobaSmall MoleculeGABRA1, GABRB2, GABRG2, GLRA1, PLA2G2A, SLC6A26
DB019551,4-ButanediolSmall MoleculeMAN1B1, PLA2G2A, PLA2G2E3
DB020801-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)BenzeneSmall MoleculePLA2G2A1
DB02325Isopropyl AlcoholSmall MoleculeACP5, ADI1, AHCY, CHIT1, DCXR, DDX39B, GCH1, GDF5, GM2A, PLA2G2A, ......15
DB02448N-Tridecanoic AcidSmall MoleculePLA2G1B, PLA2G2A, PLA2G2E3
DB02504[3-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Propyl-]-Phosphonic AcidSmall MoleculePLA2G2A1
DB029364-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Butyric AcidSmall MoleculePLA2G2A1
DB03017Lauric AcidSmall MoleculeADH5, C8G, GLTP, GM2A, HNF4A, LTF, LY96, PLA2G2A, PLA2G2D, PPARA, ......12
DB03121(1-Benzyl-5-methoxy-2-methyl-1H-indol-3-yl)acetic acidSmall MoleculePLA2G2A1
DB034716-Phenyl-4(R)-(7-Phenyl-Heptanoylamino)-Hexanoic AcidSmall MoleculePLA2G2A1
DB03784ElaidoylamideSmall MoleculePLA2G2A1
DB041121-Octadecyl-2-Acetamido-2-Deoxy-Sn-Glycerol-3-Phosphoethylmethyl SulfideSmall MoleculePLA2G2A1
DB04287(S)-5-(4-Benzyloxy-Phenyl)-4-(7-Phenyl-Heptanoylamino)-Pentanoic AcidSmall MoleculePLA2G2A1
DB04786SuraminSmall MoleculeF2, FSHR, P2RY2, PLA2G2A, RYR1, SIRT56
DB05737Varespladib methylSmall MoleculePLA2G10, PLA2G2A2